Type I allergic reaction to rituximab upon first lifetime exposure: a case report.
V PolitoA BarbackiGhislaine Annie C IsabwePublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)
Our case illustrates the importance of heightened awareness by physicians that type I IgE-mediated reactions after first exposure to monoclonal antibodies such as rituximab are possible, and if unrecognized, could be potentially life-threatening.